	US 11,723,348 B2
	Genetically modified mice expressing humanized CD47
Yuelei Shen, Beijing (CN); Yang Bai, Beijing (CN); Jian Ni, Beijing (CN); Rui Huang, Beijing (CN); Chengzhang Shang, Beijing (CN); and Yanan Guo, Beijing (CN)
Assigned to Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing (CN)
Filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing (CN)
Filed on Nov. 2, 2020, as Appl. No. 17/87,487.
Application 17/087,487 is a division of application No. 16/435,368, filed on Jun. 7, 2019, granted, now 10,918,095.
Application 16/435,368 is a continuation of application No. PCT/CN2018/081628, filed on Apr. 2, 2018.
Claims priority of application No. 201710205646.7 (CN), filed on Mar. 31, 2017; and application No. 201711039543.4 (CN), filed on Oct. 27, 2017.
Prior Publication US 2021/0120790 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/027 (2006.01)

CPC A01K 67/0278 (2013.01) [A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01)]

13 Claims

1. A genetically modified mouse whose genome comprises a nucleic acid sequence encoding a chimeric CD47 comprising a humanized extracellular region and five endogenous transmembrane domains, wherein the nucleic acid sequence is operably linked to an endogenous CD47 promoter and the mouse functionally expresses the chimeric CD47.